Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates

Documenti analoghi

• Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults
  di: Mohamed‐Eslam F Mohamed, et al.
  Pubblicazione: (2024)
• Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate
  di: Tim Tippin, et al.
  Pubblicazione: (2024)
• Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
  di: Yingxue Chen, et al.
  Pubblicazione: (2025)
• A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer
  di: Michael J. Hanley, et al.
  Pubblicazione: (2025)
• Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy Adults
  di: Thomas M. Polasek, et al.
  Pubblicazione: (2026)